| Affiliation: | 1. Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio;2. Fox Chase Cancer Center, Philadelphia, Pennsylvania;3. Duke Cancer Institute, Durham, North Carolina;4. University of Texas MD Anderson Cancer Center, Houston, Texas;5. Washington University School of Medicine, Siteman Cancer Center, St. Louis, Missouri;6. Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada;7. Mount Sinai School of Medicine, New York, New York;8. Georgia Cancer Coalition Distinguished Scholar, Winship Cancer Institute, Emory University, Atlanta, Georgia;9. University of Pennsylvania, Philadelphia, Pennsylvania;10. Johns Hopkins University School of Medicine, Baltimore, Maryland;11. University of Michigan, Ann Arbor, Michigan;12. University of Pittsburgh, Pittsburgh, Pennsylvania;13. Henry Ford Hospital, Detroit, Michigan;14. Mayo Clinic, Rochester, Minnesota;15. Fred Hutchinson Cancer Research Center, Seattle, Washington;16. Dana‐Farber Cancer Institute, Boston, Massachusetts;17. University of Minnesota, Minneapolis, Minnesota;18. Karmanos Cancer Institute, Wayne State University, Detroit, Michigan;19. Ohio State University Comprehensive Cancer Center, Columbus, Ohio;20. National Cancer Institute, Bethesda, Maryland |
| Abstract: | Recent advances now permit resection of many pharyngeal tumors through the open mouth, an approach that can greatly reduce the morbidity of surgical exposure. These transoral techniques are being rapidly adopted by the surgical community and hold considerable promise. On November 6–7, 2011, the National Cancer Institute sponsored a Clinical Trials Planning Meeting to address how to further investigate the use of transoral surgery, both in the good prognosis human papillomavirus (HPV)–initiated oropharyngeal cancers, and in those with HPV‐unrelated disease. The proceedings of this meeting are summarized. © 2012 Wiley Periodicals, Inc. Head Neck, 2012 |
